Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies

American Journal of Gastroenterology

Volumn 106, Issue 7, 2011, Pages 1209-1218

  Ngamruengphong, Saowanee ^a   Leontiadis, Grigorios I ^b   Radhi, Saba ^a   Dentino, Andrew ^a   Nugent, Kenneth ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; VITAMIN D;

DRUG MEGADOSE; DRUG USE; FRACTURE; HIP FRACTURE; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; SPINE FRACTURE; SYSTEMATIC REVIEW; TREATMENT DURATION; VERTEBRA FRACTURE; WRIST FRACTURE;

FRACTURES, BONE; HUMANS; INCIDENCE; PROTON PUMP INHIBITORS;

EID: 79960055410     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.113     Document Type: Review

References (34)

1. Burge R, Dawson-Hughes B, Solomon DH et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22: 465-75. (Pubitemid 46797130)
2. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-100.
3. Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38.
4. Pallarito K. How safe are popular reflux drugs? Experts debate evidence linking acid-blockers to possible bone heart problems. US News World Rep 2009.
5. O ' Connell MB, Madden DM, Murray AM e t al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118: 778-81. (Pubitemid 40897665)
6. Mizunashi K, Furukawa Y, Katano K et al. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993; 53: 21-5. (Pubitemid 23187327)
7. U.S. Food and Drug Administration (FDA). Proton Pump Inhibitors (PPI): Class Labeling Change. Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213321. htm. Accessed 15 October 2010.
8. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology. JAMA 2000; 283: 2008-12.
9. Loke YK, Price D, Herxheimer A, Cochrane Adverse Effects Methods Group. Systematic reviews of adverse Effects: framework for a structured approach. BMC Med Res Methodol 2007; 7: 32.
10. Levine M. Harm (observational studies). In: Gordon Guyatt, Drummond Rennie, Maureen Meade, Deborah Cook (eds). Users ' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 2nd edn, McGraw-Hill: New York, USA, 2008, pp 361-81.
11. Guyatt GH, Oxman AD, Vist G, for the GRADE Working Group et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6. (Pubitemid 351632017)
12. StatsDirect Statistical Soft ware Version 2.7.8. StatsDirect Ltd: England, 2008.
13. Loke YK, Price D, Herxheimer A. Chapter 14: Adverse Effects. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 (updated September 2008). The Cochrane Collaboration, 2008. Available from http://www.cochrane-handbook.org. Accessed 15 October 2010.
14. Yang YX, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53. (Pubitemid 46021498)
15. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79: 76-83. (Pubitemid 44306164)
16. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28: 951-9.
17. Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 2008; 83: 251-9.
18. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-26.
19. de Vries F, Cooper AL, Cockle SM et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20: 1989-98.
20. Roux C, Briot K, Gossec L et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84: 13-9.
21. Pouwels S, Lalmohamed A, Souverein P et al. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2010; 22: 903-10.
22. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170: 765-71.
23. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139: 93-101.
24. Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2002; 2: 1.
25. Roughead EE, McGeechan K, Sayer GP. Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 2004; 57: 813-6. (Pubitemid 38748050)
26. McGowan B, Bennett K, Barry M. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice. Pharmacoepidemiol Drug Saf 2010; 19: 763-9.
27. Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 2010; 138: 896-904.
28. Valuck RJ, Ruscin JM. A case-control study on adverse Effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57: 422-8. (Pubitemid 38609284)
29. McLean RR, Jacques PF, Selhub J e t al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 2042-9. (Pubitemid 38596555)
30. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004; 350: 2033-41.
31. Lubec B, Fang-Kircher S, Lubec T et al. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996; 1315: 159-62. (Pubitemid 26128323)
32. Kado DM, Bucur A, Selhub J et al. Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging. Am J Med 2002; 113: 537-42. (Pubitemid 35379907)
33. Kuo HK, Liao KC, Leveille SG et al. Relationship of homocysteine levels to quadriceps strength, gait speed, and late-life disability in older adults. J Gerontol A Biol Sci Med Sci 2007; 62: 434-9. (Pubitemid 47071702)
34. Lau J, Ioannidis JP, Terrin N e t al. The case of the misleading funnel plot. BMJ 2006; 333: 597-600. (Pubitemid 44433638)